ALX Oncology Holdings Inc (ALXO) stock
ALXONasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 3/30
$1.00+0.00 (+0.50%)
Close on Nov 17, 2026Market cap $138.97MP/E –Yield –
ALX Oncology ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
ALX Oncology's ebitda for the twelve months ending Jun 30, 2026 was -$81.95M. For fiscal 2025 it was -$103.32M. The highest annual figure on record is -$13.25M in fiscal 2018.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$103.32M | – |
| FY2024 | Dec 31, 2024 | -$141.60M | – |
| FY2023 | Dec 31, 2023 | -$169.44M | – |
| FY2022 | Dec 31, 2022 | -$127.09M | – |
| FY2021 | Dec 31, 2021 | -$83.50M | – |
| FY2020 | Dec 31, 2020 | -$43.46M | – |
| FY2019 | Dec 31, 2019 | -$18.75M | – |
| FY2018 | Dec 31, 2018 | -$13.25M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$17.93M | – |
| Q1 FY2026 | Mar 31, 2026 | -$18.82M | – |
| Q4 FY2025 | Dec 31, 2025 | -$22.87M | – |
| Q3 FY2025 | Sep 30, 2025 | -$22.33M | – |
| Q2 FY2025 | Jun 30, 2025 | -$26.45M | – |
| Q1 FY2025 | Mar 31, 2025 | -$31.61M | – |
| Q4 FY2024 | Dec 31, 2024 | -$30.40M | – |
| Q3 FY2024 | Sep 30, 2024 | -$32.37M | – |
| Q2 FY2024 | Jun 30, 2024 | -$41.33M | – |
| Q1 FY2024 | Mar 31, 2024 | -$37.55M | – |
| Q4 FY2023 | Dec 31, 2023 | -$47.82M | – |
| Q3 FY2023 | Sep 30, 2023 | -$53.08M | – |
| Q2 FY2023 | Jun 30, 2023 | -$36.58M | – |
| Q1 FY2023 | Mar 31, 2023 | -$31.99M | – |
| Q4 FY2022 | Dec 31, 2022 | -$32.11M | – |
| Q3 FY2022 | Sep 30, 2022 | -$36.58M | – |
| Q2 FY2022 | Jun 30, 2022 | -$33.69M | – |
| Q1 FY2022 | Mar 31, 2022 | -$24.69M | – |
| Q4 FY2021 | Dec 31, 2021 | -$28.44M | – |
| Q3 FY2021 | Sep 30, 2021 | -$24.58M | – |
| Q2 FY2021 | Jun 30, 2021 | -$16.30M | – |
| Q1 FY2021 | Mar 31, 2021 | -$14.20M | – |
| Q4 FY2020 | Dec 31, 2020 | -$17.82M | – |
| Q3 FY2020 | Sep 30, 2020 | -$9.71M | – |
| Q2 FY2020 | Jun 30, 2020 | -$10.69M | – |
| Q1 FY2020 | Mar 31, 2020 | -$5.13M | – |
| Q4 FY2019 | Dec 31, 2019 | -$7.62M | – |
| Q3 FY2019 | Sep 30, 2019 | -$2.93M | – |
| Q2 FY2019 | Jun 30, 2019 | -$4.09M | – |
See a number that looks wrong?